Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
Authors
Keywords
-
Journal
Journal of Oncology
Volume 2020, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2020-03-10
DOI
10.1155/2020/9258396
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
- (2019) Mustapha Abubakar et al. MODERN PATHOLOGY
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
- (2018) Jordi Rodon et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
- (2018) Thomas A. Werfel et al. CANCER RESEARCH
- Mammalian target of rapamycin complex 2 (mTORC2) controls glycolytic gene expression by regulating Histone H3 Lysine 56 acetylation
- (2018) Raghavendra Vadla et al. CELL CYCLE
- mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
- (2018) Amin Ardestani et al. Cell Metabolism
- PI3K inhibition to overcome endocrine resistance in breast cancer
- (2018) Niamh M Keegan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway
- (2018) Liyan Du et al. Molecular Medicine Reports
- Implication of the PI3K/Akt/mTOR Pathway in the Process of Incompetent Valves in Patients with Chronic Venous Insufficiency and the Relationship with Aging
- (2018) Miguel A. Ortega et al. Oxidative Medicine and Cellular Longevity
- Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer
- (2018) Cancer Discovery
- mTORC1 as the main gateway to autophagy
- (2017) Yoana Rabanal-Ruiz et al. Essays in Biochemistry
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
- (2017) Sibylle Loibl et al. EUROPEAN JOURNAL OF CANCER
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- DNA damage repair in breast cancer and its therapeutic implications
- (2017) Reem Ali et al. PATHOLOGY
- Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis
- (2017) Shuting Li et al. Oncotarget
- Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
- (2017) Floriana Morgillo et al. Oncotarget
- CC-115, a dual inhibitor of mTOR Kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
- (2017) Toshiya Tsuji et al. Oncotarget
- AKT in cancer: new molecular insights and advances in drug development
- (2016) Prabhjot S. Mundi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- (2016) Angel Guerrero-Zotano et al. CANCER AND METASTASIS REVIEWS
- Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors
- (2016) Jie Jiang et al. CANCER RESEARCH
- Calcium-Sensing Receptor Promotes Breast Cancer by Stimulating Intracrine Actions of Parathyroid Hormone–Related Protein
- (2016) Wonnam Kim et al. CANCER RESEARCH
- A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
- (2016) C. X. Ma et al. CLINICAL CANCER RESEARCH
- Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer
- (2016) Aleksandra M Ochnik et al. ENDOCRINE-RELATED CANCER
- Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches
- (2016) Katarzyna Switon et al. IUBMB LIFE
- Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer
- (2016) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
- (2016) Joachim Weischenfeldt et al. NATURE GENETICS
- IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
- (2016) Gerjon J. Ikink et al. Nature Communications
- Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer
- (2016) Nina Kozlova et al. Oncotarget
- Cancer statistics: Breast cancer in situ
- (2015) Elizabeth M. Ward et al. CA-A CANCER JOURNAL FOR CLINICIANS
- mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells
- (2015) Govindasamy-Muralidharan Karthik et al. CANCER LETTERS
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells
- (2015) Ji Yinghua et al. Clinical Laboratory
- Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, inAkt1E17K mutation positive advanced solid tumors
- (2015) David M. Hyman et al. MOLECULAR CANCER THERAPEUTICS
- Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines
- (2015) Euphemia Y. Leung et al. PLoS One
- Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
- (2015) Mark A. Feitelson et al. SEMINARS IN CANCER BIOLOGY
- Signal Transduction in Cancer
- (2015) R. Sever et al. Cold Spring Harbor Perspectives in Medicine
- mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis
- (2015) Meghan M. Morrison et al. PLoS Genetics
- The associations between Parkinson’s disease and cancer: the plot thickens
- (2015) Danielle D. Feng et al. Translational Neurodegeneration
- INPP4B: the New Kid on the PI3K Block
- (2015) Irina U. Agoulnik et al. Oncotarget
- Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
- (2015) Nicole M. Davis et al. Oncotarget
- GSK-3 as potential target for therapeutic intervention in cancer
- (2015) James A. McCubrey et al. Oncotarget
- Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
- (2015) Pradip De et al. NEOPLASIA
- PI3K/AKT signaling pathway and cancer: an updated review
- (2014) Miriam Martini et al. ANNALS OF MEDICINE
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
- (2014) Yuichi Ando et al. CANCER SCIENCE
- A Genetic Polymorphism (rs17251221) in the Calcium-Sensing Receptor is Associated with Breast Cancer Susceptibility and Prognosis
- (2014) Xiaoyan Li et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Clinical and Prognostic Significance of HIF-1α, PTEN, CD44v6, and Survivin for Gastric Cancer: A Meta-Analysis
- (2014) Jing Chen et al. PLoS One
- Everolimus in hormone receptor–positive advanced breast cancer: Targeting receptor-based mechanisms of resistance
- (2013) Mikhail I. Shtivelband BREAST
- DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin
- (2013) Wojciech M. Ciszewski et al. BREAST CANCER RESEARCH AND TREATMENT
- Gain of Interaction with IRS1 by p110α-Helical Domain Mutants Is Crucial for Their Oncogenic Functions
- (2013) Yujun Hao et al. CANCER CELL
- The complex genetic landscape of familial breast cancer
- (2013) Lorenzo Melchor et al. HUMAN GENETICS
- Effect of IRS4 Levels on PI 3-Kinase Signalling
- (2013) Gerta Hoxhaj et al. PLoS One
- Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer
- (2012) Antje Krohn et al. AMERICAN JOURNAL OF PATHOLOGY
- Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
- (2012) Yesim Gökmen-Polar et al. BREAST CANCER RESEARCH AND TREATMENT
- P3-16-01: Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma.
- (2012) J Rodon et al. CANCER RESEARCH
- Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer
- (2012) Sylvie M. Guichard et al. CANCER RESEARCH
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Role of melatonin on electromagnetic radiation-induced oxidative stress and Ca2+signaling molecular pathways in breast cancer
- (2012) Mustafa Nazıroğlu et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- Cross-Talk between NFkB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis
- (2012) Azhar R. Hussain et al. PLoS One
- Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer
- (2012) CANHUI JIN et al. Experimental and Therapeutic Medicine
- FoxO transcription factors; Regulation by AKT and 14-3-3 proteins
- (2011) Guri Tzivion et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- The insulin receptor substrate 4 gene (IRS4) is mutated in paediatric T-cell acute lymphoblastic leukaemia
- (2011) Kristina Karrman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Ambient air pollution is associated with the increased incidence of breast cancer in US
- (2011) Yudan Wei et al. INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH
- GDC-0941 Inhibits Metastatic Characteristics of Thyroid Carcinomas by Targeting both the Phosphoinositide-3 Kinase (PI3K) and Hypoxia-Inducible Factor-1α (HIF-1α) Pathways
- (2011) Natalie Burrows et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells
- (2011) Xiao-Hong Zhang Molecular Medicine Reports
- Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer
- (2011) E P Booy et al. ONCOGENE
- The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
- (2010) E. J. Macaskill et al. BREAST CANCER RESEARCH AND TREATMENT
- Second AKT: The rise of SGK in cancer signalling
- (2010) Maressa A. Bruhn et al. GROWTH FACTORS
- Will Molecular Classification Replace Traditional Breast Pathology?
- (2010) Stuart J. Schnitt INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- Expression and function of the insulin receptor substrate proteins in cancer
- (2009) Katerina Mardilovich et al. Cell Communication and Signaling
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- The nuts and bolts of AGC protein kinases
- (2009) Laura R. Pearce et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- EGFR family: Structure physiology signalling and therapeutic targets†
- (2008) Antony W. Burgess GROWTH FACTORS
- Identification of Cellular Proteins That Interact with the Adeno-Associated Virus Rep Protein
- (2008) K. Nash et al. JOURNAL OF VIROLOGY
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now